Basilea Pharmaceutica valuation
Valuation
The P/E ratio is 18.1. The average price target of 5 analysts is CHF 99.62.
Data as of November 21, 2026
Basilea Pharmaceutica compared with similar companies
Basilea Pharmaceutica's P/E (trailing 12 months): 18.1, +23% against the median of a group of 7 similar companies (14.7).
| Metric | Basilea Pharmaceutica | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 18.1 | 14.7 | 4.92 – 28.1 | Middle |
| Forward P/E | 12.6 | 52.3 | 19.9 – 96.9 | Low |
| EV/EBITDA | 13.3 | 13.3 | 12.4 – 15.8 | Middle |
| Price/book | 5.55 | 4.45 | 2.62 – 5.35 | High |
| Price/sales | 3.64 | 4.20 | 3.13 – 22.7 | Middle |
| Gross margin | 38.5% | 87.2% | 71.5% – 93.2% | Low |
| Operating margin | 24.2% | 19.6% | -70.7% – 36.9% | Middle |
| Net margin | 21.2% | 10.5% | 0.0% – 43.9% | Middle |
| ROE | 39.5% | 16.3% | -5.5% – 27.7% | High |
| Debt/equity | 0.51 | 0.05 | 0.03 – 0.34 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Basilea Pharmaceutica: valuation over time
On the latest fiscal year's earnings (2025), Basilea Pharmaceutica's P/E today is 23.2, below the median of its last 4 fiscal years (29.2; between 7.10 and 44.9 from 2022 to 2025). Relative to earnings, the stock costs less than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | CHF 54.70 | CHF 3.14 | 17.4 |
| 2024 | CHF 41.35 | CHF 5.82 | 7.10 |
| 2023 | CHF 35.30 | CHF 0.86 | 41.0 |
| 2022 | CHF 45.80 | CHF 1.02 | 44.9 |
| 2021 | CHF 40.92 | -CHF 0.58 | — |
| 2020 | CHF 53.15 | -CHF 1.43 | — |
| 2019 | CHF 46.86 | -CHF 2.08 | — |
| 2018 | CHF 39.96 | -CHF 2.89 | — |
| 2017 | CHF 75.90 | -CHF 1.79 | — |
| 2016 | CHF 73.10 | -CHF 5.07 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- CHF 901.05M
- Enterprise value
- CHF 812.09M
- PEG
- -0.08
- EV/revenue
- 3.28
Profitability and growth
- ROA
- 13.7%
- ROIC
- 16.8%
- Revenue growth (year over year)
- 14.5%
- Earnings growth (year over year)
- 64.4%
Financial health
- Total cash
- CHF 173.05M
- Total debt
- CHF 83.44M
- Current ratio
- 6.60
- Quick ratio
- 5.81
- Altman Z-Score
- 1.21
- Piotroski F-Score
- 6.00
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- April 11, 2013
Analysts and estimates
- Average price target
- CHF 99.62
- Median price target
- CHF 110.00
- High price target
- CHF 126.10
- Low price target
- CHF 67.00
- Analysts with a price target
- 5
- Consensus
- Buy
- Forward EPS
- CHF 5.76
- EPS estimate, current year
- CHF 6.59
Shares and trading
- Beta
- 0.32
- Average volume
- 44.78K
- Shares outstanding
- 12.39M
- Float
- 11.31M
- Institutional ownership
- 30.7%
- Insider ownership
- 0.6%
